SM

Steven T. Miller

AR Alcon Research: 8 patents #24 of 267Top 9%
AU Alcon Universal: 6 patents #3 of 80Top 4%
AL Alcon Laboratories: 4 patents #65 of 314Top 25%
AP Arrowhead Pharmaceuticals: 4 patents #29 of 121Top 25%
AL Alcon: 3 patents #271 of 866Top 35%
AR Arrowhead Research: 2 patents #3 of 49Top 7%
YC Yamanouchi Pharmaceutical Co.: 1 patents #277 of 516Top 55%
📍 Arlington, TX: #27 of 1,708 inventorsTop 2%
🗺 Texas: #4,299 of 125,132 inventorsTop 4%
Overall (All Time): #139,036 of 4,157,543Top 4%
28
Patents All Time

Issued Patents All Time

Showing 1–25 of 28 patents

Patent #TitleCo-InventorsDate
9765340 RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders John M. Yanni, Jon E. Chatterton, Daniel A. Gamache 2017-09-19
9745585 RNAi-mediated inhibition of histamine receptor H1-related conditions John M. Yanni, Jon E. Chatterton, Daniel A. Gamache 2017-08-29
9453220 RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders John M. Yanni, John E. Chatterton, Daniel A. Gamache 2016-09-27
9447419 RNAi-mediated inhibition of tumor necrosis factor α-related conditions John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache 2016-09-20
9371529 RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions John M. Yanni, Jon E. Chatterton, Daniel A. Gamache 2016-06-21
9206428 RNAi-mediated inhibition of histamine receptor H1-related conditions John M. Yanni, Jon E. Chatterton, Daniel A. Gamache 2015-12-08
8865671 RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions John M. Yanni, Jon E. Chatterton, Daniel A. Gamache 2014-10-21
8673873 RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders John M. Yanni, Jon E. Chatterton, Daniel A. Gamache 2014-03-18
8618278 RNAi-mediated inhibition of histamine receptor H1-related conditions John M. Yanni, Jon E. Chatterton, Daniel A. Gamache 2013-12-31
8541389 RNAi-mediated inhibition of tumor necrosis factor α-related conditions John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache 2013-09-24
8222227 RNAi-mediated inhibition of histamine receptor H1-related conditions John M. Yanni, Jon E. Chatterton, Daniel A. Gamache 2012-07-17
8048863 RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions John M. Yanni, Jon E. Chatterton, Daniel A. Gamache 2011-11-01
8017592 RNAi-mediated inhibition of histamine receptor H1-related conditions John M. Yanni, Jon E. Chatterton, Daniel A. Gamache 2011-09-13
7906512 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases Mark R. Hellberg, Andrew Rusinko 2011-03-15
7799778 5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases Mark R. Hellberg, Andrew Rusinko 2010-09-21
7732421 RNAI-mediated inhibition of tumor necrosis factor α-related conditions John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache 2010-06-08
7713975 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases Mark R. Hellberg, Andrew Rusinko 2010-05-11
6506802 Disulfide derivatives useful for treating allergic diseases Zixia Feng, Mark R. Hellberg 2003-01-14
6500864 Disulfide derivatives useful for treating allergic diseases Zixia Feng, Mark R. Hellberg 2002-12-31
6492418 Compositions containing a benzamide disulfide derivative for treating allergic diseases Mark R. Hellberg, Zixia Feng 2002-12-10
6492552 Disulfide derivatives useful for treating allergic diseases Zixia Feng, Mark R. Hellberg 2002-12-10
6452052 Aniline disulfide derivatives for treating allergic diseases Mark R. Hellberg, Zixia Feng 2002-09-17
6372802 Aniline disulfide derivatives for treating allergic diseases Mark R. Hellberg, Zixia Feng 2002-04-16
6274160 Methods of use of histamine H2 agonists in treating dry eye Daniel A. Gamache, John M. Yanni 2001-08-14
6225327 Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complications Mark R. Hellberg, John M. Yanni 2001-05-01